Patient characteristics and graft composition
| . | Study group (n = 31) . | Control group (n = 26) . |
|---|---|---|
| Diagnosis | ||
| ALL | 16 | 13 |
| AML | 7 | 4 |
| CML | 6 | 7 |
| JMML | 2 | 2 |
| Age, y* | 10 (1.5-24) | 11.5 (4-20) |
| Weight, kg* | 31 (9.6-98) | 34 (16-72) |
| Disease status | ||
| Complete remission 1 | 4 | 2 |
| Complete remission 2/3 | 16 | 14 |
| Chronic phase 1/2 | 5 | 9 |
| Active disease | 6 | 1 |
| HLA match | ||
| Matched | 15 | 24 |
| Mismatched | ||
| 1 antigen | 13 | 2 |
| 2 antigens | 3 | 0 |
| Graft composition* | ||
| CD34+ cell purity | 98.5% (85%-99.4%) | ND |
| Cell dose | ||
| CD34+ stem cells × 106/kg | 8.0 (1-54) | ND |
| CD3+ T cells × 103/kg | 6 (0.5-34) | ND |
| . | Study group (n = 31) . | Control group (n = 26) . |
|---|---|---|
| Diagnosis | ||
| ALL | 16 | 13 |
| AML | 7 | 4 |
| CML | 6 | 7 |
| JMML | 2 | 2 |
| Age, y* | 10 (1.5-24) | 11.5 (4-20) |
| Weight, kg* | 31 (9.6-98) | 34 (16-72) |
| Disease status | ||
| Complete remission 1 | 4 | 2 |
| Complete remission 2/3 | 16 | 14 |
| Chronic phase 1/2 | 5 | 9 |
| Active disease | 6 | 1 |
| HLA match | ||
| Matched | 15 | 24 |
| Mismatched | ||
| 1 antigen | 13 | 2 |
| 2 antigens | 3 | 0 |
| Graft composition* | ||
| CD34+ cell purity | 98.5% (85%-99.4%) | ND |
| Cell dose | ||
| CD34+ stem cells × 106/kg | 8.0 (1-54) | ND |
| CD3+ T cells × 103/kg | 6 (0.5-34) | ND |
ND indicates not done.
Median (range).